Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Holding MRNS?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.3Last Year’s EPS
-$0.74Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -30.81%
|Next Earnings Date:Mar 11, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and global expansion for ZTALMY, alongside significant clinical progress in the TrustTSC trial. However, financial losses, challenges with the IV ganaxolone program, and cost-cutting measures indicate some underlying challenges.Company Guidance
In the Marinus Pharmaceuticals Q2 2024 earnings call, the company highlighted several key metrics and guidance for the future. ZTALMY, their commercial product for CDKL5 deficiency disorder, achieved net product revenue of $8 million for the quarter, representing an 85% growth from the prior year. The company anticipates full-year 2024 revenues between $33 million and $35 million. They also shared plans for a supplemental NDA submission for ZTALMY in tuberous sclerosis complex by April 2025, targeting a PDUFA date in late 2025. Marinus' restructuring efforts have reduced SG&A and R&D expenses by 30%, extending their cash runway into Q2 2025. The company aims to achieve profitability 12 to 18 months post-TSC launch, supported by a second manufacturing facility to meet global demand.ZTALMY Revenue Growth
ZTALMY generated net product revenue of $8 million in Q2 2024, representing growth of over 85% compared to the same period in 2023.
Global Expansion of ZTALMY
ZTALMY was approved in China in July 2024 as the first treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients 2 years of age and older.
Phase III TrustTSC Trial Progress
The TrustTSC trial for treating seizures associated with tuberous sclerosis complex (TSC) completed enrollment in May 2024, with top-line data expected in the first half of Q4 2024.
Pipeline Expansion Plans
Marinus plans to initiate a proof-of-concept trial with ZTALMY for the treatment of developmental and epileptic encephalopathies, including Lennox-Gastaut syndrome, in the first half of 2025.
---
MRNS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRNS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $0.34 | $0.30 | -11.76% |
| Aug 13, 2024 | $1.23 | $1.18 | -4.07% |
| May 08, 2024 | $1.57 | $1.43 | -8.92% |
| Mar 05, 2024 | $9.54 | $9.24 | -3.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Marinus (MRNS) report earnings?
Marinus (MRNS) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Marinus (MRNS) earnings time?
Marinus (MRNS) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRNS EPS forecast?
MRNS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.3.
---